Viral hepatitis.
According to the WHO over 2 billion people in the world are infected with viral hepatitis. About 20 million people suffer acute viral hepatitis annually, about 10% of them become chronic patients. Hepatitis B is transmitted 10 times better than HIV. Viral hepatitis C has even higher incidence rate. This type of hepatitis results in chronic form in 70-80% of cases. Unfavorable outcomes of viral hepatitis are: cirrhosis and hepatic cancer (hepatocellular carcinoma).
As of today there is a topical problem of searching for preparations activating specific reactions of cellular and humoral immunity, having antiviral effects and causing no side effects after long term use and introduction of such preparations in treatment of viral hepatitis. Nowadays generally accepted therapeutic regimen includes combination of preparations (interferon+ribovirin and others). Although there exists a group of preparations having antiviral effects, they are contraindicated in the following conditions: decompensated hepatic diseases, autoimmune diseases, severe somatic diseases, thrombocytopenia, drug abuse, alcohol ingestion, use of psychoactive drugs, depression. These preparations are tolerated badly by patients (resistance to therapy is 38%, cost of treatment course with various schemes is 10 times higher than cost of treatment with EnergoIod).
- EnergoIod has antiviral effect (there is no necessity of combining it with other preparations);
- EnergoIod has detoxication and membrane-stabilizing actioneffects on hepatic cells;
- EnergoIod normalizes metabolic processes in liver and ensures restoration of biochemical characteristics of blood;
- The preparation has adsorption effect, it improves condition in cholestatic syndrome;
- It allows to reduce number of chronic complications of viral hepatitis;
- It has immunomodulatory effect;
- It has anti-inflammatory effect;
- It improves condition in concomitant diseases;
- It has detoxication effect;
- Inclusion of the preparation in combination therapy allows to avoid unfavorable outcome of hepatitis such as cirrhosis and hepatic cancer;
- Cost of the preparation justifies its application, this preparation is an alternative to other treatment methods;
- This preparation is tolerated by patients much better.
Using EnergoIod preparations you can expand opportunities for treating hepatic diseases.
Use of EnergoIod in this disease
Use of EnergoIod in this disease
Weight, kg
For disease
Lung disease
Average disease
Severe disease
Single dose, ml
Daily dose, ml
Single dose, ml
Daily dose, ml
Single dose, ml
Daily dose, ml
40
2
4
4
8
6
12
50-60
3
6
6
12
9
18
70-80
4
8
8
16
12
24
90-100
5
10
10
20
15
30
110-120
6
12
12
24
17
34
Use of a concentrate
Shake before use. It requires dilution with cold or cool drinking water (in an amount of 100-200 ml).
The daily dose calculated for 1 kg body weight, depending on the severity and course of the disease is 0.1-0.3 ml / kg body weight / day, divided into 2 doses.
The drug is taken on an empty stomach in the morning and in the evening before going to bed for 30 days.
If necessary, a second course in 15 days.
The number of courses per year depending on the severity of the pathological process.
Carrying out an accelerated rate with the maximum dose for 15 days.